Wen, WH, et al.
A review of strategies to prevent mother-to-infant transmission of hepatitis B virus infection. Expert Review of Gastroenterology and Hepatology
2015; 17: 1–14.
Chen, DS. From hepatitis to hepatoma: Lessons from type B. viral hepatitis. Science
1993; 262: 369–370.
Cheng, HR, et al.
Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS ONE
2013; 8: e53008.
Sorrell, MF, et al.
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Annals of Internal Medicine
2009; 150: 104–110.
Lok, AS, et al.
Chronic hepatitis B. Hepatology
2007; 45: 507–539.
Liaw, YF, et al.
Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology
1991; 13: 627–631.
Sampliner, RE, et al.
The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. American Journal of the Medical Sciences
1979; 277: 17–22.
Villeneuve, JP, et al.
A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology
1994; 106: 1000–1005.
Da Silva, LC, et al.
Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection. Journal of Gastroenterology
1996; 31: 696–701.
Chu, CM, et al.
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology
2007; 45: 11871–1192.
Han, ZG, et al.
HBsAg spontaneous seroclearance in a cohort of HBeAg-seronegative patients with chronic hepatitis B virus infection. Journal of Medical Virology
2016; 88: 79–85.
Chu, CM, et al.
Hepatitis B surface antigen seroclearance during chronic HBV infection. Antiviral Therapy
2010; 15: 133–143.
Kim, GA, et al.
Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. Journal of Hepatology
2015; 62: 1092–1099.
Liu, J, et al.
A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. Journal of Hepatology
2013; 58: 853–860.
Fang, ZL, et al.
HBV A1762 T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. American Journal of Gastroenterology
2008; 103: 2254–2262.
Courouce-Pauty, AM, et al.
Distribution of HBsAg subtype in the world. Vox Sanguinis
1983; 44: 197–211.
Okamoto, H, et al.
Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. Journal of General Virology
1988; 69: 2575–2583.
Chen, X, et al.
A description of the hepatitis B virus genomic background in a high-prevalence area in China. Virology Journal
2014; 11: 101.
BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series
1999; 41: 95–98.
Tamura, K, et al.
MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Molecular Biology and Evolution
2013; 30: 2725–2729.
Perrillo, R, et al.
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transplantation
2013; 19: 887–895.
Hsu, C, et al.
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology
2014; 59: 2092–2100.
Jang, JW, et al.
Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS ONE
2015; 10: e0122041.
Han, JW, et al.
Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatology Research
2016; 46: 657–668.
Waite, J, et al.
Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS
1988; 2: 443–448.
Vento, S, et al.
Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet
1989; 1: 332–333.
Fattovich, G, et al.
Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Journal of Hepatology
2008; 48: 335–352.
Deguchi, M, et al.
Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. Journal of Virology Methods
2004; 115: 217–222.
Ferreira, SC, et al.
Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Annals of Hepatology
2014; 13: 762–70.
Lauret, E, et al.
Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. Liver International
2015; 35: 140–147.
Lazarevic, I, et al.
Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia. Journal of Medical Virology
2010; 82: 1160–1167.
Martin, CM, et al.
Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. Journal of Viral Hepatitis
2012; 19: 716–723.